Home › Companies › CAPR

Capricor Therapeutics

CAPR Rare disease Lead: NDA Submitted 2 Biotech Distilled articles ↓

Neurology Cell

Most recent annual filing: 2026-03-17

Pipeline (1 active programs)

Deramiocel

Cell

Duchenne Muscular Dystrophy NDA Submitted intravenous Nippon Shinyaku

Technology platforms

StealthX

Engineered exosome platform for vaccine and therapeutic development; supports targeted RNA, protein, and small molecule delivery; focus areas include infectious diseases, monogenic diseases, and other indications

Biotech Distilled coverage (2)

2026-06-26 UPDATE: Capricor Therapeutics (CAPR) — A Third Binary Lands on the Calendar
2026-06-19 Capricor Therapeutics (CAPR) — Scientific Deep Dive for Deramiocel and the StealthX Exosome Platform

Articles open on Substack. Some deep dives are subscriber-only.